Evidence map›Paper›PMID 37446186›Full record

ArticleInternational journal of molecular sciences2023

Different Kinetics of Serum ADAMTS13, GDF-15, and Neutrophil Gelatinase-Associated Lipocalin in the Early Phase of Aneurysmal Subarachnoid Hemorrhage.

Peter Csecsei, Csaba Olah, Reka Varnai, Diana Simon, Szabina Erdo-Bonyar, Timea Berki, Mate Czabajszki, Laszlo Zavori, Attila Schwarcz, Tihamer Molnar

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Peter CsecseiDepartment of Neurosurgery, Medical School, University of Pecs, 7624 Pecs, Hungary.
Csaba OlahNeurosurgical Unit, B.A.Z. County Hospital, 3526 Miskolc, Hungary.
Reka VarnaiDepartment of Primary Health Care, Medical School, University of Pecs, 7624 Pecs, Hungary.ORCID 0000-0001-8440-3955
Diana SimonDepartment of Immunology and Biotechnology, Medical School, University of Pecs, 7624 Pecs, Hungary.
Szabina Erdo-BonyarDepartment of Immunology and Biotechnology, Medical School, University of Pecs, 7624 Pecs, Hungary.
Timea BerkiDepartment of Immunology and Biotechnology, Medical School, University of Pecs, 7624 Pecs, Hungary.
Mate CzabajszkiNeurosurgical Unit, B.A.Z. County Hospital, 3526 Miskolc, Hungary.
Laszlo ZavoriEmergency Department, Saudi German Hospital, Dubai 391093, United Arab Emirates.ORCID 0000-0002-1715-4167
Attila SchwarczDepartment of Neurosurgery, Medical School, University of Pecs, 7624 Pecs, Hungary.
Tihamer MolnarDepartment of Anaesthesiology and Intensive Care, Medical School, University of Pecs, 7624 Pecs, Hungary.ORCID 0000-0002-6149-9787
University of Pecs · HUUniversity of Miskolc · HUDubai Hospital · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growth differentiation factor 15 (GDF-15), neutrophil gelatinase-associated lipocalin (NGAL), and ADAMTS13 have previously been implicated in the pathophysiological processes of SAH. In the present study, we aim to examine their role in the early period of SAH and their relationship to primary and secondary outcomes. Serum samples were collected at five time periods after SAH (at 24 h (D1), at 72 h (D3), at 120 h (D5), at 168 h (D7) and at 216 h (D9), post-admission) and) were measured by using MILLIPLEX Map Human Cardiovascular Disease (CVD) Magnetic Bead Panel 2. We included 150 patients with SAH and 30 healthy controls. GDF-15 levels at D1 to D9 were significantly associated with a 3-month unfavorable outcome. Based on the ROC analysis, in patients with a good clinical grade at admission (WFNS I-III), the GDF-15 value measured at time point D3 predicted a 3-month unfavorable outcome (cut-off value: 3.97 ng/mL, AUC:0.833, 95%CI: 0.728-0.938, sensitivity:73.7%, specificity:82.6%,

Indexed as

Growth Differentiation Factor 15Subarachnoid HemorrhageADAMTS13 ProteinHospitalizationHumansKineticsLipocalin-2ADAMTS13 ProteinADAMTS13 protein, humanGrowth Differentiation Factor 15Lipocalin-2ADAMTS13delayed cerebral ischemiaGDF-15macrovascular vasospasmneutrophil gelatinase-associated lipocalinsubarachnoid hemorrhage

Identifiers

PMID37446186
PMCPMC10341640
OpenAlexW4382981592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.